CalAmp (CAMP) Stock

CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced that management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference to be held at the Lotte New York Palace Hotel in New York City December 3rd – 5th, 2024.

- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M

In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4's common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive Phase 1 safety results for treating urea cycle disorders, with no concerning safety trends observed. The urea cycle disorders market is moderate in size, with a low expected growth rate, but Camp4 aims to broaden into larger markets.

CARLSBAD, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- OEM Off-Highway, the nationally recognized magazine serving product development teams for mobile OEMs globally, has selected the HMU-3640LB Industrial IoT Gateway as one of the favored new mobile on- and off-road equipment products of 2024.

CARLSBAD, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- CalAmp Corp. (“CalAmp”), a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, is pleased to announce the appointment of Thomas Ayers as General Manager of its Edge Device business. In this role, Ayers will spearhead the growth and innovation of CalAmp's edge device portfolio, leveraging his extensive expertise in hardware development and leading-edge technology.

Carowinds' Historic Investment Includes Two Major New Family Attractions Carowinds' Historic Investment Includes Two Major New Family Attractions

CARLSBAD, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CalAmp, a global leader in telematics solutions, is excited to announce the launch of the new Inventory Manager feature. This feature is designed to reduce operational friction and streamline the device onboarding process by providing enhanced visibility and oversight of shipped products.